Loading...
XSHE
300009
Market cap2.04bUSD
Jun 13, Last price  
8.95CNY
1D
-2.19%
1Q
1.13%
Jan 2017
19.19%
IPO
178.12%
Name

Anhui Anke Biotechnology Group Co Ltd

Chart & Performance

D1W1MN
P/E
20.70
P/S
5.77
EPS
0.43
Div Yield, %
2.79%
Shrs. gr., 5y
0.54%
Rev. gr., 5y
8.17%
Revenues
2.54b
-11.51%
127,769,584125,874,083156,490,022190,643,971227,930,127267,916,554337,940,099430,346,122542,405,933635,755,075849,216,4341,096,268,3151,461,550,2031,712,529,6691,701,417,2162,168,765,2052,331,062,7272,865,752,0592,536,042,781
Net income
707m
-16.56%
15,727,07822,713,57234,552,89444,570,47151,983,69163,322,66073,945,18289,870,067109,851,477136,254,700197,302,805277,742,623263,171,602124,465,864358,955,394206,629,495703,260,285847,229,426706,948,363
CFO
685m
-30.42%
29,662,11435,098,07926,043,95438,674,86547,427,2117,180,61153,800,82553,213,032108,684,214118,734,165258,005,072280,625,013287,490,590295,627,531464,796,376592,171,625698,977,608985,011,682685,371,947
Dividend
May 27, 20240.25 CNY/sh

Profile

Anhui Anke Biotechnology (Group) Co., Ltd. develops, produces, and markets pharmaceutical products in China and internationally. The company offers recombinant human growth hormone for injection under the Ansomone name; and recombinant human interferon alpha 2b lyophilized powder, liquid, and prefilled syringe for injection, as well as recombinant human interferon alpha 2b cream, eye drop, and suppository under the Anterferon name. It also provides anti-sperm antibody, semen leukocyte peroxidase staining, one-time semen processing, sperm hypo-osmotic staining, sperm life detection, sperm staining detection, sperm acrosin detection, sperm DNA fragmentation staining, and leptin and immunohistochemical diagnostic kits. In addition, the company offers adhesive plasters, oral solutions, topical preparations, and ointments; peptide APIs; beauty care and anti-aging products; and synthetic drugs in the form of oral powders, dripping pills, and tablets and capsules. Further, it provides autosomal, sex chromosome, autosomal and sex chromosome combination, and other kits, as well as paternity testing set packages; tumor biological immunotherapy products; and DNA testing professional services. The company was founded in 2000 and is based in Hefei, China.
URL
https://www.ankebio.com/
IPO date
Oct 30, 2009
Employees
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
2,536,043
-11.51%
2,865,752
22.94%
2,331,063
7.48%
Cost of revenue
1,413,828
1,458,980
1,436,999
Unusual Expense (Income)
NOPBT
1,122,214
1,406,773
894,063
NOPBT Margin
44.25%
49.09%
38.35%
Operating Taxes
87,179
61,341
96,129
Tax Rate
7.77%
4.36%
10.75%
NOPAT
1,035,036
1,345,432
797,935
Net income
706,948
-16.56%
847,229
20.47%
703,260
240.35%
Dividends
(411,050)
(327,542)
Dividend yield
2.46%
2.14%
Proceeds from repurchase of equity
(3,000)
BB yield
0.02%
Debt
Debt current
5,003
9,081
Long-term debt
76,494
95,635
48,126
Deferred revenue
121,526
114,162
Other long-term liabilities
113,522
2
Net debt
(733,223)
(1,764,548)
(1,110,286)
Cash flow
Cash from operating activities
685,372
985,012
698,978
CAPEX
(195,336)
Cash from investing activities
(643,018)
Cash from financing activities
(407,289)
FCF
706,263
1,097,387
597,409
Balance
Cash
1,443,879
1,455,799
1,167,492
Long term investments
(629,159)
404,383
Excess cash
687,917
1,716,894
1,050,939
Stockholders' equity
3,468,187
3,565,427
3,312,271
Invested Capital
3,776,796
2,376,777
2,426,877
ROIC
33.64%
56.02%
36.93%
ROCE
25.09%
34.28%
25.42%
EV
Common stock shares outstanding
1,683,210
1,634,278
1,635,489
Price
8.64
-15.46%
10.22
9.19%
9.36
-28.50%
Market cap
14,542,938
-12.93%
16,702,323
9.11%
15,308,177
-28.62%
EV
13,985,340
15,132,708
14,390,979
EBITDA
1,243,309
1,509,825
980,638
EV/EBITDA
11.25
10.02
14.68
Interest
2,405
2,941
1,522
Interest/NOPBT
0.21%
0.21%
0.17%